Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical has completed participant enrollment for its XanaMIA phase 2b/3 clinical trial, aimed at evaluating its novel Alzheimer’s treatment, Xanamem. The trial enrolled 246 participants, exceeding the initial target, which enhances its statistical power. Data will be assessed through an interim analysis in early 2026, with topline results anticipated by November 2026. This milestone underscores the potential of Xanamem as a groundbreaking, once-daily oral therapy designed to control brain cortisol, with implications for Alzheimer’s patients and the broader neurotherapeutic market.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing innovative therapies to address neurological and neuropsychiatric conditions linked to dysregulated brain cortisol levels. The company’s lead product, Xanamem, aims to enhance cognitive function and address brain health issues caused by elevated cortisol, a hormone associated with memory, attention, and reasoning impairments.
Average Trading Volume: 4,377,104
Technical Sentiment Signal: Buy
Current Market Cap: A$171.9M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.